Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Announces Pricing of Convertible Senior Notes

Published: Monday, June 09, 2014
Last Updated: Monday, June 09, 2014
Bookmark and Share
The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

Illumina, Inc. today announced the pricing of an offering of $550 million aggregate principal amount of its 0% convertible senior notes due 2019 (the "2019 Notes") and $450 million aggregate principal amount of its 0.5% convertible senior notes due 2021 (the "2021 Notes" and, together with the 2019 Notes, the "Notes"). The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Illumina has granted the initial purchasers an option to purchase up to an additional $82.5 million aggregate principal amount of the 2019 Notes and $67.5 million aggregate principal amount of the 2021 Notes on the same terms and conditions referenced above. The 2019 Notes will not bear interest and will mature on June 15, 2019, unless earlier repurchased or converted. Interest on the 2021 Notes will be paid semi-annually at a rate of 0.50% per year and the Notes will mature on June 15, 2021, unless earlier repurchased or converted.

The Notes will be convertible, subject to the satisfaction of certain conditions, into cash, shares of Illumina common stock or a combination thereof, at Illumina's election. Prior to March 15, 2019 (in the case of the 2019 Notes) or March 15, 2021 (in the case of the 2021 Notes), the Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time through the second scheduled trading day immediately preceding the maturity date. The initial conversion rate of both the 2019 Notes and the 2021 Notes is 3.9318 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $254.34 per share of common stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of 55% relative to the last reported sale price on June 5, 2014 of Illumina's common stock of $164.09.

The aggregate net proceeds to Illumina from the offering of the 2019 Notes and 2021 Notes will be approximately $985 million, exclusive of any proceeds attributable to the initial purchasers' possible exercise of their options to purchase additional Notes. Illumina expects to use the net proceeds from the offering and cash on hand to fund repurchases of up to $600 million aggregate principal amount of its outstanding 0.25% Convertible Senior Notes due 2016 (the "2016 Notes") through privately negotiated transactions. The offering is expected to close on June 11, 2014, subject to customary closing conditions.



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina and 10x Genomics Announce Co-Marketing Relationship
Illumina and 10x Genomics have announced building partnership to promote 10x Genomics linked-read sequencing products and Illumina sequencing systems.
Thursday, February 11, 2016
Illumina Files Patent Infringement Suit in the UK Against Premaitha Health
Suit is filed for Infringement of NIPT Patents.
Monday, March 16, 2015
Illumina Revenues Jump 35 Percent
Company’s Third Quarter 2014 Results Announced.
Tuesday, October 21, 2014
Initial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular Pathology
The selection of three startup companies for the inaugural Illumina Accelerator funding cycle are announced.
Wednesday, October 15, 2014
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Tuesday, July 22, 2014
Novogene Acquires an Illumina HiSeq X Ten Sequencing System
First-in-China deal Iincreases Novogene's investment in Illumina's Next-Generation Sequencing technology.
Thursday, February 13, 2014
Illumina Awarded FDA Contract for NGS Technology to Identify Foodborne Pathogens
Agency selects MiSeq® system for program to explore NGS as mechanism to enhance food safety.
Wednesday, September 19, 2012
Macrogen, Inc. Increases Investment in Illumina’s Next-Generation Sequencing Technology
New purchase includes ten HiSeq 2000®Systems, HiSeq 2500® upgrades, and two MiSeq®Systems.
Thursday, March 22, 2012
Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer
Urges stockholders not to tender their shares, company considers offer inadequate.
Wednesday, February 08, 2012
Scientific News
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Gene Behind Rare Childhood Syndrome Identified
Online activism by one patient’s mother spurred research collaboration which led to the identification of a new genetic syndrome.
Resilience Project Identifies Rare Unaffected Individuals
Researchers from Mount Sinai and Sage Bionetworks report analysis of nearly 600,000 genomes for resilience project.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Children With Cancer To Get New Gene Test
Pilot study will sequence 81 cancer genes in children’s tumours to help personalise cancer treatment.
How The Bat Got Its Wings
Finding may provide clues to human limb development and malformations.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!